Physicians
Overview
Cellvizio system
Education
Reimbursement
GastroEnterology
Barrett’s Esophagus
Pancreatic Cysts
Gastric Disease
Inflammatory Bowel Diseases
Irritable Bowel Syndrome
Bilio-Pancreatic Strictures
Colorectal Lesions
Pulmonology
Lung Nodules
Covid-19
Urology
Investors
About us
Our story
Team
Board of Directors
Leadership
Join Us
Press Coverage
Commercial Network
News & events
US
INT
FR
US
INT
FR
Contact
Search
Search
News - Cellvizio
-
Nov 4, 2016
Reimbursement increases of 131% for hospitals and 86% for ambulatory surgical centers for key Cellvizio procedures
Click to read more
You might also like to read
NEWS - Cellvizio
Oct 31, 2022
Mauna Kea Technologies Announces Success of Clinical Trial on Prediction of Remission in Patients with Inflammatory Bowel Disease (IBD) and its Publication in Gastroenterology
Discover
NEWS - Cellvizio
Apr 12, 2022
Mauna Kea Technologies Announces First of Its Kind U.S. FDA 510(k) Clearance for Use of Cellvizio in a New Category of Molecular Imaging-guided Endoscopic, Laparoscopic, Needle-Based Procedures
Discover
NEWS - Cellvizio
Jul 11, 2022
Tasly Pharmaceuticals and Mauna Kea Technologies Announce Joint Venture and Licensing Agreements
Discover
